Cargando…
Therapeutic management options for stage III non-small cell lung cancer
Lung cancer is the leading cause of cancer death worldwide. Majority of newly diagnosed lung cancers are non-small cell lung cancer (NSCLC), of which up to half are considered locally advanced at the time of diagnosis. Patients with locally advanced stage III NSCLC consists of a heterogeneous popula...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5309711/ https://www.ncbi.nlm.nih.gov/pubmed/28246582 http://dx.doi.org/10.5306/wjco.v8.i1.1 |
_version_ | 1782507753722347520 |
---|---|
author | Yoon, Stephanie M Shaikh, Talha Hallman, Mark |
author_facet | Yoon, Stephanie M Shaikh, Talha Hallman, Mark |
author_sort | Yoon, Stephanie M |
collection | PubMed |
description | Lung cancer is the leading cause of cancer death worldwide. Majority of newly diagnosed lung cancers are non-small cell lung cancer (NSCLC), of which up to half are considered locally advanced at the time of diagnosis. Patients with locally advanced stage III NSCLC consists of a heterogeneous population, making management for these patients complex. Surgery has long been the preferred local treatment for patients with resectable disease. For select patients, multi-modality therapy involving systemic and radiation therapies in addition to surgery improves treatment outcomes compared to surgery alone. For patients with unresectable disease, concurrent chemoradiation is the preferred treatment. More recently, research into different chemotherapy agents, targeted therapies, radiation fractionation schedules, intensity-modulated radiotherapy, and proton therapy have shown promise to improve treatment outcomes and quality of life. The array of treatment approaches for locally advanced NSCLC is large and constantly evolving. An updated review of past and current literature for the roles of surgery, chemotherapeutic agents, radiation therapy, and targeted therapy for stage III NSCLC patients are presented. |
format | Online Article Text |
id | pubmed-5309711 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Baishideng Publishing Group Inc |
record_format | MEDLINE/PubMed |
spelling | pubmed-53097112017-02-28 Therapeutic management options for stage III non-small cell lung cancer Yoon, Stephanie M Shaikh, Talha Hallman, Mark World J Clin Oncol Review Lung cancer is the leading cause of cancer death worldwide. Majority of newly diagnosed lung cancers are non-small cell lung cancer (NSCLC), of which up to half are considered locally advanced at the time of diagnosis. Patients with locally advanced stage III NSCLC consists of a heterogeneous population, making management for these patients complex. Surgery has long been the preferred local treatment for patients with resectable disease. For select patients, multi-modality therapy involving systemic and radiation therapies in addition to surgery improves treatment outcomes compared to surgery alone. For patients with unresectable disease, concurrent chemoradiation is the preferred treatment. More recently, research into different chemotherapy agents, targeted therapies, radiation fractionation schedules, intensity-modulated radiotherapy, and proton therapy have shown promise to improve treatment outcomes and quality of life. The array of treatment approaches for locally advanced NSCLC is large and constantly evolving. An updated review of past and current literature for the roles of surgery, chemotherapeutic agents, radiation therapy, and targeted therapy for stage III NSCLC patients are presented. Baishideng Publishing Group Inc 2017-02-10 2017-02-10 /pmc/articles/PMC5309711/ /pubmed/28246582 http://dx.doi.org/10.5306/wjco.v8.i1.1 Text en ©The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved. http://creativecommons.org/licenses/by-nc/4.0/ Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
spellingShingle | Review Yoon, Stephanie M Shaikh, Talha Hallman, Mark Therapeutic management options for stage III non-small cell lung cancer |
title | Therapeutic management options for stage III non-small cell lung cancer |
title_full | Therapeutic management options for stage III non-small cell lung cancer |
title_fullStr | Therapeutic management options for stage III non-small cell lung cancer |
title_full_unstemmed | Therapeutic management options for stage III non-small cell lung cancer |
title_short | Therapeutic management options for stage III non-small cell lung cancer |
title_sort | therapeutic management options for stage iii non-small cell lung cancer |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5309711/ https://www.ncbi.nlm.nih.gov/pubmed/28246582 http://dx.doi.org/10.5306/wjco.v8.i1.1 |
work_keys_str_mv | AT yoonstephaniem therapeuticmanagementoptionsforstageiiinonsmallcelllungcancer AT shaikhtalha therapeuticmanagementoptionsforstageiiinonsmallcelllungcancer AT hallmanmark therapeuticmanagementoptionsforstageiiinonsmallcelllungcancer |